Mesenchymal Stem Cells (MSCs) as a Potential Therapeutic Strategy in COVID-19 Patients: Literature Research

Area of Science:

• Regenerative Medicine
• Immunotherapy
• Cell and Molecular Biology

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, presents significant global health challenges with increasing critical cases and limited treatments.
• COVID-19-induced pneumonia can lead to severe lung conditions including Acute Lung Injury (ALI)/Acute Respiratory Distress Syndrome (ARDS), extensive inflammation, and cytokine storms.

Purpose of the Study:

• To analyze Mesenchymal Stem Cells (MSCs), including their origin, differentiation, and therapeutic potential.
• To explore MSCs as a potential therapeutic strategy for COVID-19, bridging their properties with the disease's characteristics.
• To review recent studies on MSC-based therapies for treating COVID-19 patients.

Main Methods:

• Analysis of MSCs' origin, differentiation, and immunomodulatory/anti-inflammatory properties.
• Review of existing literature on MSC applications in lung pathologies.
• Examination of recent clinical studies involving MSC-based therapies for COVID-19.

Main Results:

• MSCs possess immunomodulatory and anti-inflammatory activities beneficial for treating lung pathologies.
• Previous studies show positive outcomes for MSCs in other lung diseases.
• Emerging evidence suggests MSCs offer hopeful and effective therapies for severe COVID-19, mitigating adverse symptoms.

Conclusions:

• MSCs represent a significant therapeutic opportunity for managing COVID-19 and its severe respiratory complications.
• The immunomodulatory and regenerative properties of MSCs are key to their potential effectiveness against virus-induced lung injury.
• Continued research and clinical application of MSC-based therapies are warranted for COVID-19 treatment.